MVision AI
MVision AI is a Helsinki-based medical software company that builds AI-powered radiotherapy planning tools. Its Workspace+ platform and GBS™ suite deliver automated organ contouring, dose prediction, and synthetic imaging for cancer centers globally.
- Company typePrivate
- Founded2017
- HeadquartersHelsinki, Finland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What MVision AI does
MVision AI is a Helsinki, Finland-based medical software company founded in 2017 that develops AI-powered solutions for radiotherapy treatment planning. The company's product architecture is organized around two commercial offerings: GBS™ (Guideline-Based Segmentation), which bundles the Contour+ auto-segmentation engine with the Guide training and assessment module and the Verify quality-assurance module; and the Workspace+ platform, which integrates Contour+, Dose+ (AI dose prediction for prostate and pelvic radiotherapy), Image+ (synthetic CT for MRI-only workflows), and Adapt+ (contour propagation for adaptive radiotherapy). Underlying technology consists of deep learning models trained on multi-institutional imaging datasets and aligned with international contouring guidelines, achieving a reported median vDSC of 0.88 in clinical evaluations and up to 95% manual-work-time reduction in radiotherapy planning workflows.
The company monetizes through B2B medical-device software licensing on a recurring subscription basis, selling directly to enterprise radiotherapy departments and cancer centers and indirectly via a distributor network (including Synektik in Poland and Meditest in France) and TPS integration partners (Varian, Elekta). Pricing is not publicly disclosed and is typically negotiated per institution. As of the latest data, the platform has been used to treat over 100,000 patients across 14 countries and 40+ clinics. The company maintains a wholly-owned US subsidiary (MVision AI Inc., headquartered in Delray Beach with a San Antonio office) for HIPAA-compliant US market operations. Regulatory footprint is broad, with FDA 510(k) clearances for both Contour+ and Dose+ (Dose+ in September 2025), CE marking, and market approvals in Australia (TGA), Singapore (HSA), UAE, and Morocco. The IAEA/Aarhus University Hospital ELAISA research partnership extends reach into 22 low- and middle-income countries.
MVision AI firmographics
Firmographics- Name
- MVision AI
- Legal name
- MVision AI
- Website
- https://mvision.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MVision AI is a Helsinki-based medical software company that builds AI-powered radiotherapy planning tools. Its Workspace+ platform and GBS™ suite deliver automated organ contouring, dose prediction, and synthetic imaging for cancer centers globally.
- Ownership category
- akta.pro rank
MVision AI industry classification
Industry- Product category
- Radiotherapy Treatment Planning Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where MVision AI is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices3 records
Markets served
MVision AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Medical Device Software Licensing: MVision AI develops and commercializes AI-powered medical device software solutions (Contour+, Dose+, Image+, Adapt+) for radiotherapy planning. The company operates as a medical software company with products requiring regulatory approvals (FDA 510(k), CE, TGA) for clinical use in various markets.
- Post Seed Financing: The company raised 5.4 million euros in Post Seed financing to accelerate its AI-powered radiotherapy planning solution development and commercialization.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
MVision AI product offering
Product offeringCore offering
MVision AI develops and sells a SaaS-based, AI-powered medical device software platform for radiotherapy treatment planning. The offering centers on two integrated solutions—GBS™ (Guideline-Based Segmentation combining Contour+, Guide, and Verify) and Workspace+ (unified platform integrating Contour+, Dose+, Image+, and Adapt+)—that automate organ contouring, dose prediction, synthetic imaging, and adaptive planning to accelerate cancer treatment workflows.
Product overview
MVision AI offers a platform-plus-modules architecture centered on two main solutions: GBS™ (Guideline-Based Segmentation) and Workspace+. GBS™ is a comprehensive solution combining three modules—Contour+ (AI auto-contouring), Guide (contouring training and assessment), and Verify (contour validation)—designed to standardize segmentation and reduce variability. Workspace+ is the unified AI platform that integrates multiple independent modules: Contour+ for auto-segmentation, Dose+ for AI dose prediction, Image+ for synthetic CT imaging, and Adapt+ for contour propagation and adaptation. Both solutions are designed for radiotherapy workflows and support flexible adoption, with modules operating independently or together. The company has received FDA 510(k) clearance, CE certification, and market approvals across multiple countries including Australia, Singapore, UAE, Morocco, and the USA.
Differentiator
Problem solved
Functional benefit
Brands
- GBS™: Guideline-Based Segmentation solution combining Contour+, Guide, and Verify for standardized radiotherapy contouring.
- Workspace+™
- Contour+
- Dose+
- Image+
- Adapt+
- Guide
- Verify
Products and services
- GBS™ (Guideline-Based Segmentation) Comprehensive guideline-based segmentation solution for radiotherapy departments that combines AI auto-contouring (Contour+), contouring skills training (Guide), and contour quality assurance (Verify) to standardize planning and reduce inter-clinician variability.
- Workspace+ Unified AI platform for radiotherapy workflows that brings together contouring, synthetic CT imaging, AI dose prediction, and adaptive contour propagation in one secure environment with flexible modular adoption.
- Contour+ AI-powered auto-contouring module that automatically delineates organs at risk and anatomical structures on CT and MRI images for radiotherapy planning across multiple body sites.
- Dose+ AI-powered dose prediction module within Workspace+ that delivers rapid estimation of dose distribution maps to accelerate radiotherapy treatment planning, clinically validated for prostate and pelvic lymph node cases.
- Image+ Synthetic CT imaging module within Workspace+ that generates synthetic CT images from MRI to support MRI-only radiotherapy treatment planning workflows.
- Adapt+ Contour adaptation module within Workspace+ that rapidly propagates and adapts contours to anatomical changes during radiotherapy, supporting adaptive radiotherapy workflows.
- Guide Training and competency assessment module within GBS that benchmarks clinicians against international contouring guidelines and provides feedback to build contouring expertise.
- Verify Quality assurance module within GBS that validates AI-generated contours against manual contours and monitors inter- and intra-observer variation across the radiotherapy team.
Quantifiable outcome
- Platform used to treat over 100,000 patients across 14 countries
- +8 more outcomes
Companies that use MVision AI
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles2 records
MVision AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
MVision AI partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and flagship.
- SynektikcoreSynektik is a distributor of MVision AI products in Poland, listed on the company's distributor page. They handle local sales, implementation support, and customer relationships for MVision AI solutions in the Polish market.
- MeditestcoreMeditest is a partner of MVision AI mentioned in the context of SFPM Scientific Days 2026 event, where they will be present together at the conference in Lyon, France.
- Varian (Siemens Healthineers)coreMVision AI solutions are designed for seamless integration with Varian treatment planning systems including TrueBeam, TrueBeam STx, Clinac, and Halcyon. Multiple customer sites use MVision AI alongside Varian equipment.
- ElektacoreMVision AI solutions integrate with Elekta treatment planning systems. Clinical sites including Vivantes Berlin-Spandau and Royal Marsden use Elekta equipment alongside MVision AI.
- International Atomic Energy Agency (IAEA)flagshipIAEA partnered with MVision AI for the ELAISA project (Potential of E-Learning interventions for AI-assisted contouring Skills in Radiotherapy), a joint initiative with Aarhus University Hospital evaluating AI-assisted contouring in 22 low- and middle-income countries with 97 radiation oncologists participating.
- Aarhus University HospitalflagshipJoint research partner with IAEA on the ELAISA project, evaluating the impact of e-learning interventions combined with AI-assisted contouring on head and neck cancer OAR delineation skills in radiation oncologists from low- and middle-income countries.
- ESTRO (European Society for Therapeutic Radiology and Oncology)coreMVision AI collaborates with ESTRO through research presentations at ESTRO conferences, participation in educational workshops, and integration of ESTRO contouring guidelines in product development. The ELAISA project used ESTRO School contouring specialists for training.
- Turku University HospitalflagshipFirst university test hospital for MVision AI products in 2017-2018. Ongoing research collaboration agreement valid until 2027. The site conducts clinical testing of new modules (Image+, Adapt+, Dose+) and provides feedback for product development.
- St. Luke's Radiation Oncology Network (SLRON)flagshipIreland's largest radiotherapy provider treating 5,500+ patients annually. Uses MVision GBS across three sites with active research collaboration including 24 abstracts at ESTRO, including studies on AI auto-contouring workflows, CBCT tracking, and adaptive radiotherapy.
Scale indicators13 records
Recent moves6 records
Expansion highlights5 records
MVision AI competitors and assessment
Company assessmentBroad incumbents
- Elekta: Swedish-headquartered incumbent in linear accelerators, brachytherapy, and treatment planning software (Monaco). Like Varian, a broad incumbent in radiation oncology that MVision integrates with but that could also internalize similar AI capabilities.
- Varian (Siemens Healthineers): Global leader in radiation oncology hardware, treatment planning (Eclipse), and oncology information systems, now part of Siemens Healthineers. The TPS incumbent that MVision integrates with and a potential long-term competitor if it bundles native auto-contouring AI into Eclipse.
- GE Healthcare (Radiation Oncology): Large incumbent with imaging and oncology IT offerings that overlap with the radiotherapy planning ecosystem MVision serves. A broad ecosystem player whose strategy around AI auto-contouring could shape the competitive landscape.
- Philips (Radiation Oncology): Philips' radiation oncology portfolio includes Pinnacle treatment planning and broader oncology informatics. A broad incumbent offering overlapping capabilities in the radiotherapy workflow where MVision competes and partners.
Emerging players
- Therapanacea: Paris-based AI company applying deep learning to radiation oncology treatment planning and contouring. An emerging AI-native peer in the same radiotherapy auto-contouring and dose prediction space as MVision, with narrower commercial footprint.
Direct peers
- Radformation: US-based vendor of AI-driven workflow automation tools for radiation oncology (AutoContour, ClearCalc, EZFluence, ClearCheck). Directly competes with MVision's Contour+ and Dose+ on AI contouring and treatment planning efficiency in radiotherapy clinics.
- Limbus AI: Canadian AI company offering auto-contouring (Contour ProtégéAI) and other radiotherapy planning software. Directly competes with MVision on AI auto-segmentation for radiation therapy planning, particularly in clinic-by-clinic sales motions.
- RaySearch Laboratories: Swedish-headquartered vendor of RayStation treatment planning software and the RayCare oncology information system. Directly competes with MVision in radiation oncology planning workflows, including developing its own machine learning auto-contouring capabilities within RayStation.
- Mirada Medical: Oxford-based medical imaging AI company specializing in auto-contouring and image registration for radiation oncology and diagnostic imaging. Overlaps directly with MVision's Contour+ on AI auto-segmentation and serves the same radiotherapy department buyer.
- MIM Software: US-based medical imaging AI vendor with products for radiation oncology contouring, deformable registration, and theranostics. Overlaps with MVision on AI-driven radiotherapy workflow tools and serves similar hospital radiology and radiation oncology customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
MVision AI social profiles
Digital presenceMVision AI compliance and trust
Trust signalCompliance4 records
MVision AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
MVision AI leadership team
Management profileNumber of profiles
Profiles4 records
MVision AI subsidiaries and ownership
Company hierarchySubsidiaries1 record
MVision AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MVision AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MVision AI
What does MVision AI do?
MVision AI develops and sells a SaaS-based, AI-powered medical device software platform for radiotherapy treatment planning. The offering centers on two integrated solutions—GBS™ (Guideline-Based Segmentation combining Contour+, Guide, and Verify) and Workspace+ (unified platform integrating Contour+, Dose+, Image+, and Adapt+)—that automate organ contouring, dose prediction, synthetic imaging, and adaptive planning to accelerate cancer treatment workflows.
Is MVision AI a public or private company?
MVision AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was MVision AI founded?
MVision AI was founded in 2017. It employs 51 to 100 people.
Where is MVision AI based?
MVision AI is headquartered in Helsinki, Finland, in the Europe region.
How does MVision AI make money?
Two revenue lines are on record. Medical Device Software Licensing is the primary driver. The others are post Seed Financing.
Who are MVision AI's main competitors?
Broad incumbents on record are Elekta, Varian (Siemens Healthineers), GE Healthcare (Radiation Oncology) and Philips (Radiation Oncology). Therapanacea is listed as an emerging player. Direct peers are Radformation, Limbus AI, RaySearch Laboratories, Mirada Medical and MIM Software.
Does MVision AI have an API?
No public API is recorded for MVision AI.
What industry is MVision AI in?
MVision AI's product category is Radiotherapy Treatment Planning Software. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 3391 and its SIC code is 7372.